A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting

ISRCTN ISRCTN72335887
DOI https://doi.org/10.1186/ISRCTN72335887
ClinicalTrials.gov number NCT00169819
Secondary identifying numbers H4S-CA-0050
Submission date
05/01/2005
Registration date
04/02/2005
Last edited
18/10/2007
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Olivier Bertrand
Scientific

2725 Chemin Ste Foy
Quebec
G1V 4G5
Canada

Phone +1 418 656 8711 ext 3136
Email olivier.bertrand@crhl.ulaval.ca

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designSingle-centre
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymEArly discharge after trans-radial Stenting of coronarY arteries: The EASY study
Study objectives1. Discharge on the same day after uncomplicated trans-radial coronary artery stenting is safe and effective.
2. Hospitalized patients can be safely returned to the referring center the same day following trans-radial coronary artery stenting.
3. Abciximab given as a single bolus with optimal trans-radial coronary artery stenting is as safe and effective as bolus + 12 hrs perfusion and does not hamper early discharge.
4. Same-day discharge is cost-effective and increases patient satisfaction.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedAngina
InterventionPatients with stable or unstable angina referred for catheterization and possible percutaneous intervention are eligible.

After diagnostic trans-radial catheterization, patients receive a bolus of Abciximab and undergo dilatation and stent implantation. At the end of the uncomplicated procedure, patients are randomized between group 1: No perfusion of Abciximab and discharge 4-6 hours after PCI and group 2: Standard 12 hours Abciximab perfusion and overnight hospitalization. In case of complications, patients are included in a registry and receive standard 12 hours Abciximab perfusion. Electrocardiogram (ECG) and biology tests (creatine kinase [CK] CK-myocardial band [CK-MB], troponins) are performed before, 4-6 hours after and the next day after PCI. Clinical follow-up is performed at 24 hours, 30 days, 6 months and 1 year after PCI.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Abciximab
Primary outcome measureThe primary end-point of the study is the composite of death, myocardial infarction, repeat hospitalization, urgent revascularization, severe thrombocytopenia, access site complications and major bleedings at 30 days following stent implantation.
Secondary outcome measuresThe secondary end-point is the composite of death, myocardial infarction, repeat target vessel revascularization at 30 days, 6 months and 1 year following stent implantation. Other secondary end-points include the total hospital stay (days) between the index procedure and the first 30 days follow-up, the number of unsolicited medical visits in relation with the percutaneous procedure, index of patient satisfaction and direct and indirect costs.
Overall study start date15/10/2003
Completion date29/04/2005

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants1000
Key inclusion criteriaApproximately 1000 patients undergoing 'adhoc' percutaneous coronary intervention (PCI) will be randomized.

Inclusion Criteria:
1. Patients with documented ischemic coronary artery disease and scheduled for possible coronary artery stenting are eligible.
2. Patient must be >18 years of age.
3. Patient and treating interventional cardiologist agree for randomization.
4. Patient will be informed of the randomization process and will sign an informed consent.
5. Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.
Key exclusion criteriaCLINICAL:
1. Patients with recent (<72 hrs) Q-wave (ST elevation) acute myocardial infarction
2. History of LV ejection fraction ≤30%
3. Unstable clinical condition
4. Any complication compromising ambulation
5. Concurrent participation in other investigational study requiring prolonged hospitalization
6. Required prolonged hospitalization
7. In–cath lab transient vessel closure
8. Resuscitation per PCI
9. Hemodynamic collapse during PCI
10. Severe entry site complication upon investigator decision
11. Social isolation
12. Serious cognitive disorders
13. Femoral sheath (artery)
14. Persisting chest pain
15. No ASA prior PCI
16. Allergy to ASA or thienopyridines precluding treatment for 30 days
17. Any significant blood dyscrasia
18. PCI without stent implantation (except for bifurcation lesion or re-dilatation for in-stent restenosis)
19. International Normalised Ratio (INR) >2.0
20. Contraindication to Reopro administration

ANGIOGRAPHIC:
1. Residual dissection of grade ≥B of NHBLI classification
2. Compromised or sub-occluded branch with diameter ≥ 1 mm
3. Timi <3 post-stenting
4. Thrombus post-PCI
Date of first enrolment15/10/2003
Date of final enrolment29/04/2005

Locations

Countries of recruitment

  • Canada

Study participating centre

2725 Chemin Ste Foy
Quebec
G1V 4G5
Canada

Sponsor information

Laval Hospital Research Center (Canada)
Hospital/treatment centre

2725 Chemin Ste Foy
Quebec
G1V 4G5
Canada

Phone +1 418 656 8711
Email olivier.bertrand@crhl.ulaval.ca

Funders

Funder type

Industry

This Study is an Investigator Initiated Trial, which is supported by unrestricted grants from Eli-Lilly and Bristol-Myers-Squibb (Canada)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 12/12/2006 Yes No